



Biomarker Discovery



Clinical Trials Testing



Diagnostic Translation



AltheaDx is your partner for discovery, development and approval of gene expression and DNA polymorphism diagnostics for cancer

- Global profiling of targeted gene sets
- Cost-efficient custom assay development
- Clinical qualification and validation
- Lab-developed and CLIA-approved tests [510(k), PMA]
- GLP and CLIA testing for clinical trials
- Disease Staging/Subtyping
- Predictive Drug Response
- Toxicity Profiling
- Prognosis and Enrichment
- Diagnosis and Monitoring

AltheaDx Biomarker Capabilities:

- Broad RNA expression profiling using Affymetrix® Microarrays: Reliably and reproducibly identifies critical gene sets
- Quantification *via* multiplexed XP-PCR: Sensitive, cost-effective measurement of biomarker gene panels
- “Blood to Blocks”: Capable of analyzing a wide range of samples including blood, fresh frozen and FFPE tissues
- RNA-QC Assays to pre-qualify samples
- DNA genotyping: Identifies key mutations and SNPs
- Custom data analysis and expertise in all phases of cancer diagnostic development

AltheaDx Proprietary Biomarker Panels

- Diagnosis/prognosis of prostate cancer
- Diagnosis of childhood cancer
- Custom gene panels for targeted oncology therapeutics (with partners)

Partnering

AltheaDx is seeking partners to collaborate on these and other innovative cancer biomarker sets.

For more information, contact:

Suzanne J. Romano, PhD
Collaborations & Strategic Alliances
11040 Roselle Street
San Diego, CA 92121
sromano@altheadx.com
760-805-6010